



## Press Release

Paris, November 7<sup>th</sup>

### Kurma Partners announces a new Investment in Horama S.A.

Kurma Partners, a key European player in the financing of Innovation in Healthcare, announces a new investment of Kurma Biofund II.

**Horama SA**, a French Biotech company based in Nantes and Paris, announced the closing of a Series B round of Euro 19 million (USD 22M), led by Kurma Partners, Fund +, Pontifax and Idinvest.

The company will use the financing to develop its portfolio of gene-therapy drugs, including **HORA-PDE6B** (retinitis pigmentosa), which will soon be administered to the first-ever patient in a Phase I/II clinical trial.

**HORA-PDE6B** is a drug candidate for the treatment of retinitis pigmentosa caused by mutations in the *PDE6B* gene. This replacement gene therapy provides a non-mutated copy of the *PDE6B* gene to express a functional PDE6 $\beta$  protein. There is currently no approved treatment for retinitis pigmentosa.

The Investment in Horama is the 12th of the Fund Kurma Biofund II. Thierry Laugel will join the board of Directors of the company.

#### About Kurma Partners

Kurma Partners is a key European player in the financing of innovation in healthcare and biotechnology, notably through Kurma Biofund I and II, Kurma Diagnostics and strategic partnerships with prestigious European research and medical institutions.

[www.kurmapartners.com](http://www.kurmapartners.com)

Press contacts: NewCap - Nicolas Merigeau: +33(0)1 44 71 94 98 – [nmerigeau@newcap.fr](mailto:nmerigeau@newcap.fr)